212 related articles for article (PubMed ID: 16302271)
21. Immunohistochemical study suggesting a complementary role of kallikreins hK2 and hK3 (prostate-specific antigen) in the functional analysis of human prostate tumors.
Tremblay RR; Deperthes D; Têtu B; Dubé JY
Am J Pathol; 1997 Feb; 150(2):455-9. PubMed ID: 9033261
[TBL] [Abstract][Full Text] [Related]
22. Reduced toxicity and superior therapeutic activity of a mitomycin C lipid-based prodrug incorporated in pegylated liposomes.
Gabizon AA; Tzemach D; Horowitz AT; Shmeeda H; Yeh J; Zalipsky S
Clin Cancer Res; 2006 Mar; 12(6):1913-20. PubMed ID: 16551877
[TBL] [Abstract][Full Text] [Related]
23. Impact of liver P450 reductase suppression on cyclophosphamide activation, pharmacokinetics and antitumoral activity in a cytochrome P450-based cancer gene therapy model.
Huang Z; Raychowdhury MK; Waxman DJ
Cancer Gene Ther; 2000 Jul; 7(7):1034-42. PubMed ID: 10917206
[TBL] [Abstract][Full Text] [Related]
24. alpha2-macroglobulin and C1-inactivator are plasma inhibitors of human glandular kallikrein.
Heeb MJ; España F
Blood Cells Mol Dis; 1998 Dec; 24(4):412-9. PubMed ID: 9851894
[TBL] [Abstract][Full Text] [Related]
25. Intact free prostate-specific antigen and free and total human glandular kallikrein 2. Elimination of assay interference by enzymatic digestion of antibodies to F(ab')2 fragments.
Väisänen V; Peltola MT; Lilja H; Nurmi M; Pettersson K
Anal Chem; 2006 Nov; 78(22):7809-15. PubMed ID: 17105175
[TBL] [Abstract][Full Text] [Related]
26. Identification of a novel complex between human kallikrein 2 and protease inhibitor-6 in prostate cancer tissue.
Mikolajczyk SD; Millar LS; Marker KM; Rittenhouse HG; Wolfert RL; Marks LS; Charlesworth MC; Tindall DJ
Cancer Res; 1999 Aug; 59(16):3927-30. PubMed ID: 10463585
[TBL] [Abstract][Full Text] [Related]
27. Rapid elimination by glomerular filtration of free prostate specific antigen and human kallikrein 2 after renal transplantation.
Bruun L; Ekberg H; Bjørk T; Lilja H; Høglund P; Christensson A
J Urol; 2004 Apr; 171(4):1432-5. PubMed ID: 15017191
[TBL] [Abstract][Full Text] [Related]
28. Distribution and quantitation of the anti-trypanosomal diamidine 2,5-bis(4-amidinophenyl)furan (DB75) and its N-methoxy prodrug DB289 in murine brain tissue.
Sturk LM; Brock JL; Bagnell CR; Hall JE; Tidwell RR
Acta Trop; 2004 Jul; 91(2):131-43. PubMed ID: 15234662
[TBL] [Abstract][Full Text] [Related]
29. hK2 and free PSA, a prognostic combination in predicting minimal prostate cancer in screen-detected men within the PSA range 4-10 ng/ml.
Raaijmakers R; de Vries SH; Blijenberg BG; Wildhagen MF; Postma R; Bangma CH; Darte C; Schröder FH
Eur Urol; 2007 Nov; 52(5):1358-64. PubMed ID: 17499425
[TBL] [Abstract][Full Text] [Related]
30. Modulating paclitaxel bioavailability for targeting prostate cancer.
Kumar SK; Williams SA; Isaacs JT; Denmeade SR; Khan SR
Bioorg Med Chem; 2007 Jul; 15(14):4973-84. PubMed ID: 17502149
[TBL] [Abstract][Full Text] [Related]
31. Characterization and processing of prostate specific antigen (hK3) and human glandular kallikrein (hK2) secreted by LNCaP cells.
Väisänen V; Lövgren J; Hellman J; Piironen T; Lilja H; Pettersson K
Prostate Cancer Prostatic Dis; 1999 Mar; 2(2):91-97. PubMed ID: 12496845
[TBL] [Abstract][Full Text] [Related]
32. In vitro and in vivo prodrug therapy of prostate cancer using anti-gamma-Sm-scFv/hCPA fusion protein.
Hao XK; Liu JY; Yue QH; Wu GJ; Bai YJ; Yin Y
Prostate; 2006 Jun; 66(8):858-66. PubMed ID: 16491483
[TBL] [Abstract][Full Text] [Related]
33. Preclinical toxicity, toxicokinetics, and antitumoral efficacy studies of DTS-201, a tumor-selective peptidic prodrug of doxorubicin.
Ravel D; Dubois V; Quinonero J; Meyer-Losic F; Delord J; Rochaix P; Nicolazzi C; Ribes F; Mazerolles C; Assouly E; Vialatte K; Hor I; Kearsey J; Trouet A
Clin Cancer Res; 2008 Feb; 14(4):1258-65. PubMed ID: 18281561
[TBL] [Abstract][Full Text] [Related]
34. In vivo activity of a PSA-activated doxorubicin prodrug against PSA-producing human prostate cancer xenografts.
Khan SR; Denmeade SR
Prostate; 2000 Sep; 45(1):80-3. PubMed ID: 10960846
[TBL] [Abstract][Full Text] [Related]
35. Plasmin-activated doxorubicin prodrugs containing a spacer reduce tumor growth and angiogenesis without systemic toxicity.
Devy L; de Groot FM; Blacher S; Hajitou A; Beusker PH; Scheeren HW; Foidart JM; Noël A
FASEB J; 2004 Mar; 18(3):565-7. PubMed ID: 14734647
[TBL] [Abstract][Full Text] [Related]
36. Variants of the hK2 protein gene (KLK2) are associated with serum hK2 levels and predict the presence of prostate cancer at biopsy.
Nam RK; Zhang WW; Klotz LH; Trachtenberg J; Jewett MA; Sweet J; Toi A; Teahan S; Venkateswaran V; Sugar L; Loblaw A; Siminovitch K; Narod SA
Clin Cancer Res; 2006 Nov; 12(21):6452-8. PubMed ID: 17085659
[TBL] [Abstract][Full Text] [Related]
37. Extracellularly tumor-activated prodrugs for the selective chemotherapy of cancer: application to doxorubicin and preliminary in vitro and in vivo studies.
Trouet A; Passioukov A; Van derpoorten K; Fernandez AM; Abarca-Quinones J; Baurain R; Lobl TJ; Oliyai C; Shochat D; Dubois V
Cancer Res; 2001 Apr; 61(7):2843-6. PubMed ID: 11306455
[TBL] [Abstract][Full Text] [Related]
38. The role of a HSV thymidine kinase stimulating substance, scopadulciol, in improving the efficacy of cancer gene therapy.
Hayashi K; Lee JB; Maitani Y; Toyooka N; Nemoto H; Hayashi T
J Gene Med; 2006 Aug; 8(8):1056-67. PubMed ID: 16779868
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics and antitumor properties in tumor-bearing mice of an enediol analogue inhibitor of glyoxalase I.
Sharkey EM; O'Neill HB; Kavarana MJ; Wang H; Creighton DJ; Sentz DL; Eiseman JL
Cancer Chemother Pharmacol; 2000; 46(2):156-66. PubMed ID: 10972486
[TBL] [Abstract][Full Text] [Related]
40. Detection of prostate specific transcripts in the peripheral blood during brachytherapy predicts postoperative PSA kinetics.
Mabjeesh NJ; Amir S; Stenger A; Chen J; Matzkin H
Prostate; 2009 Aug; 69(11):1235-44. PubMed ID: 19434652
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
